← Leaderboards
John M Hoffman
University Of Utah
$3,764,344
Attributed
$8,086,311
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2007–21$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$8,086,311 · 5
By mechanism
R01$6,567,560 · 2
R21$1,178,213 · 2
P30$340,538 · 1
Top collaborators
- Kathryn Ann Morton7 shared
- Kevin M Duff5 shared
- Rheal A Towner5 shared
- Jeffrey T Yap5 shared
Most similar at University Of Utah
Same institution · by research overlap
- Andrea Hope Bild$7,326,006
- David K Gaffney$7,144,579
Others in their field
Top investigators on “Research Personnel”
- David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$364,053,504
- Judith S. Currier · University Of California Los Angeles$284,675,012
Research focus
Research PersonnelTherapeutic Clinical TrialImageSourceBaseCostLeadMissionClinical TrialsResourcesScreeningPharmaceutical PreparationsMalignant NeoplasmsCancer TherapyToxic EffectCancer CellPatient CareGeneticLaboratoriesPublishingAreaPositron-Emission TomographyLinkEvaluation
Grant awards (25)
Enriching clinical trials requiring amyloid positivity with practice effects$723,233
R01 · FY2021 · AG
Enriching clinical trials requiring amyloid positivity with practice effects$727,427
R01 · FY2020 · AG
Enriching clinical trials requiring amyloid positivity with practice effects$727,427
R01 · FY2019 · AG
Causes, consequences, imaging and mitigation of sepsis-induced encephalopathy$581,379
R01 · FY2019 · NS
Enriching clinical trials requiring amyloid positivity with practice effects$726,632
R01 · FY2018 · AG
Causes, consequences, imaging and mitigation of sepsis-induced encephalopathy$593,428
R01 · FY2018 · NS
Experimental Therapeutics Program (Project-003)$45,633
P30 · FY2018 · CA · contact PI
Experimental Therapeutics Program (Project-003)$17,857
P30 · FY2018 · CA · contact PI
Experimental Therapeutics Program (Project-003)$17,759
P30 · FY2018 · CA · contact PI
Experimental Therapeutics Program (Project-003)$16,308
P30 · FY2018 · CA · contact PI
Experimental Therapeutics Program (Project-003)$11,101
P30 · FY2018 · CA · contact PI
Experimental Therapeutics Program (Project-003)$8,928
P30 · FY2018 · CA · contact PI
Experimental Therapeutics Program (Project-003)$8,160
P30 · FY2018 · CA · contact PI
Experimental Therapeutics Program (Project-003)$4,263
P30 · FY2018 · CA · contact PI
Enriching clinical trials requiring amyloid positivity with practice effects$730,318
R01 · FY2017 · AG
Causes, consequences, imaging and mitigation of sepsis-induced encephalopathy$593,428
R01 · FY2017 · NS
Experimental Therapeutics Program (Project-003)$76,529
P30 · FY2017 · CA · contact PI
Causes, consequences, imaging and mitigation of sepsis-induced encephalopathy$576,124
R01 · FY2016 · NS
Experimental Therapeutics Program (Project-003)$77,877
P30 · FY2016 · CA · contact PI
Causes, consequences, imaging and mitigation of sepsis-induced encephalopathy$588,164
R01 · FY2015 · NS
Experimental Therapeutics Program (Project-003)$56,123
P30 · FY2015 · CA · contact PI
MULTI-TRACER PET ASSESSMENT OF RESPONSE TO NOVEL TARGETED CHEMOTHERAPY$299,900
R21 · FY2014 · CA · contact PI
MULTI-TRACER PET ASSESSMENT OF RESPONSE TO NOVEL TARGETED CHEMOTHERAPY$310,213
R21 · FY2012 · CA · contact PI
FDG-PET/CT in the evaluation of persistent febrile neutropenia in cancer patients$284,050
R21 · FY2008 · CA · contact PI
FDG-PET/CT in the evaluation of persistent febrile neutropenia in cancer patients$284,050
R21 · FY2007 · CA · contact PI